Search Immortality Topics:

Page 11234..1020..»


Category Archives: Biotechnology

Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer -…

EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced an agreement on a Phase 1b clinical trial with City of Hope, a world-renowned independent cancer research and treatment center. The trial will assess the combination of Lixtes first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).

LB-100 will be given in combination with carboplatin, etoposide and atezolizumab, an FDA approved but marginally effective regimen, in previously untreated ED-SCLC. The dose of LB-100 will be escalated with fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (RP2D). Patient entry will then be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm its safety and to look for objective evidence of potential therapeutic activity as assessed by objective response rate, duration of overall response, progression-free-survival and overall survival.

John S. Kovach, M.D., Lixte founder and chief executive officer, said Small cell lung cancer (SCLC) comprises approximately 15% of all lung cancers worldwide with about 30,000 new cases annually in the US. Although this very aggressive neuroendocrine tumor is much more sensitive to cytotoxic chemotherapy and radiation than the most common type of lung cancer, SCLC patients soon relapse after treatment and have a dismal prognosis. Recently, the addition of an immune blocker, atezolizumab, to carboplatin plus etoposide showed the first significant but modest improvement in median progression free survival from 4.3 to 5.2 months, and in median overall survival from 10.3 to 12.3 months.

Kovach continued, In animal models, LB-100 significantly enhances the antitumor activity of cytotoxic chemotherapy in general, and in particular, the combination of carboplatin and etoposide against SCLC cells without enhancing toxicity. Mice models may not be predictive for humans, but if the extensive preclinical data showing LB-100 increases the effectiveness of chemotherapy applies to patients, we should see clear evidence of therapeutic benefit even in this early trial.

Ravi Salgia, M.D., Ph.D., the trials principal investigator and City of Hopes Arthur & Rosalie Kaplan Chair in Medical Oncology, said, City of Hope is in constant pursuit of more effective therapies for its cancer patients, and this therapeutic combination could be one for patients with small cell lung cancer, which is currently difficult to treat, particularly after a patient has relapsed. We look forward to working with Lixte on this important trial that we hope will make more therapeutic options available for patients with small cell lung cancer.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader inbone marrow transplantation and immunotherapy such asCAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodiesandnumerous breakthrough cancer drugsare based on technology developed at the institution. AccessHopeTM, a wholly owned subsidiary, was launched in 2019 and isdedicated to serving employers and their health care partners by providing access to City of Hopes exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nations Best Hospitals in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, withadditional locationsthroughout Southern California and in Arizona. For more information aboutCity of Hope, follow us onFacebook,Twitter,YouTubeorInstagram.

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the on switches because the off switches, especially the master off switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, weakened by chemo or other cancer therapies, to continue to replicate, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors in the clinic, is currently being tested in three clinical studies with others in planning. lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission athttp://www.sec.gov/edgar.shtml.

Lixte Contact:info@lixte.comGeneral Phone: (631) 830-7092Investor Phone: (888) 289-5533

Link:
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte's Lead Compound LB-100 to Treat Small Cell Lung Cancer -...

Posted in Biotechnology | Comments Off on Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer -…

Is INmune Bio Inc (INMB) a Winner in the Biotechnology Industry? – InvestorsObserver

A rating of 80 puts INmune Bio Inc (INMB) near the top of the Biotechnology industry according to InvestorsObserver. INmune Bio Inc's score of 80 means it scores higher than 80% of stocks in the industry. INmune Bio Inc also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 36 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

INmune Bio Inc (INMB) stock is trading at $26.95 as of 10:09 AM on Tuesday, Jan 19, an increase of $2.13, or 8.58% from the previous closing price of $24.82. The stock has traded between $25.08 and $28.19 so far today. Volume today is low. So far 58,396 shares have traded compared to average volume of 246,327 shares.

Click Here to get the full Stock Score Report on INmune Bio Inc (INMB) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Continue reading here:
Is INmune Bio Inc (INMB) a Winner in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is INmune Bio Inc (INMB) a Winner in the Biotechnology Industry? – InvestorsObserver

Is Diffusion Pharmaceuticals Inc (DFFN) The Right Choice in Biotechnology? – InvestorsObserver

The 66 rating InvestorsObserver gives to Diffusion Pharmaceuticals Inc (DFFN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 83 percent of stocks in the Biotechnology industry, DFFNs 66 overall rating means the stock scores better than 66 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Diffusion Pharmaceuticals Inc (DFFN) stock is lower by -6.29% while the S&P 500 has risen 0.93% as of 2:05 PM on Tuesday, Jan 19. DFFN is down -$0.07 from the previous closing price of $1.13 on volume of 2,697,020 shares. Over the past year the S&P 500 has risen 14.53% while DFFN has risen 112.00%. DFFN lost -$0.49 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Diffusion Pharmaceuticals Inc (DFFN) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the original post:
Is Diffusion Pharmaceuticals Inc (DFFN) The Right Choice in Biotechnology? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Diffusion Pharmaceuticals Inc (DFFN) The Right Choice in Biotechnology? – InvestorsObserver

Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in…

ATLANTA, Ga. and SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 /PRNewswire/ -- Spelman College and IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announce partnership for professional development of the next generation of female African American leaders in the biotechnology industry through the Spelman College and IDEAYA Biosciences Health Science and Biotechnology Program.

The Spelman IDEAYA partnership is a unique academic and industry collaboration that will provide Spelman students a learning platform for pursuing a career in the biotechnology industry, through the guiding principles of mentorship and education.

The Spelman IDEAYA Health Science and Biotechnology Program will provide a professional internship and development program and scholarship for selected Spelman students who have interest in biotechnology as a potential future career path. IDEAYA's goal is to provide financial support and a unique and highly specialized experience for Spelman students with a longer-term objective to identify and develop the next generation of leaders in the biotechnology industry.

The selected students from Spelman will be sponsored by IDEAYA and be provided a summer internship at the end of the students' sophomore year. Support of the interns will continue through the students' junior and senior years through tuition scholarships, biotechnology specific educational opportunities provided by IDEAYA and biotechnology industry focused career and graduate school advice provided through an IDEAYA mentor. IDEAYA will also provide programmatic support to the Spelman Environmental and Health Sciences Department.

There will be an R&D and Business / Entrepreneurship track provided under the Spelman IDEAYA Health Science and Biotechnology Program.

"IDEAYA Biosciences mission and strategic plan closely aligns with that of Spelman College," said Rosalind Gregory-Bass, M.D., associate professor of environmental and health sciences and director of Spelman's Health Careers Program. "Cancer health disparities among people of African descent are highly significant. The desire to be at the forefront of oncology-focused precision medicine is of extreme importance to the population we serve. One key strategy to overcome these disparities is through Precision Medicine Technology. It is important to the way we as a country revolutionize medicine in the pursuit of better healthcare outcomes."

"As an institution with one of the nation's highest number of medical school applications from Black Americans, we are passionate about not only the discovery on new therapeutic options, but the delivery of the treatments as well," said Dr. Bass. "The technology being developed at IDEAYA will be pivotal to that end. Spelman students and faculty can significantly contribute to these efforts and positively impact the company, overall."

"We are ecstatic to partner with Spelman College in this scholarship program which we believe has the opportunity to identify and develop the next generation of female African American CEOs, entrepreneurs, and R&D executives and scientists in the biotechnology industry," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.

About Spelman CollegeFounded in 1881, Spelman College is a leading liberal arts college widely recognized as the global leader in the education of women of African descent. Located in Atlanta, the College's picturesque campus is home to 2,100 students. Spelman is the country's leading producer of Black women who complete Ph.D.s in science, technology, engineering and math (STEM). The College's status is confirmed by U.S. News & World Report, which ranked Spelman No. 54 among all liberal arts colleges, No. 19 for undergraduate teaching, No. 4 for social mobility among liberal arts colleges, and No. 1 for the 14th year among historically Black colleges and universities. The Wall Street Journal ranked the College No. 3, nationally, in terms of student satisfaction. Recent initiatives include a designation by the Department of Defense as a Center of Excellence for Minority Women in STEM, a Gender and Sexuality Studies Institute, the first endowed queer studies chair at an HBCU, and a program to increase the number of Black women Ph.D.s in economics. New majors have been added, including documentary filmmaking and photography, and partnerships have been established with MIT's Media Lab, the Broad Institute and the Army Research Lab for artificial intelligence and machine learning. Outstanding alumnae include Children's Defense Fund founder Marian Wright Edelman, Starbucks Group President and COO Rosalind Brewer, political leader Stacey Abrams, former Acting Surgeon General and Spelman's first alumna president Audrey Forbes Manley, actress and producer Latanya Richardson Jackson, global bioinformatics geneticist Janina Jeff and authors Pearl Cleage and Tayari Jones. For more information, visit http://www.spelman.edu.

About IDEAYA BiosciencesIDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality which represents an emerging class of precision medicine targets.

Forward-Looking StatementsThis press release contains forward-looking statements, including, but not limited to, statements related to the effects of the Spelman IDEAYA Health Science and Biotechnology Program. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA's business of the worldwide COVID-19 pandemic, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

View original content to download multimedia:http://www.prnewswire.com/news-releases/spelman-college-and-ideaya-biosciences-announce-partnership-for-professional-development-of-the-next-generation-of-female-african-american-leaders-in-the-biotechnology-industry-301209801.html

SOURCE IDEAYA Biosciences, Inc.

Company Codes: NASDAQ-NMS:IDYA

Link:
Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in...

Posted in Biotechnology | Comments Off on Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in…

Is Ampio Pharmaceuticals Inc (AMPE) the Top Pick in the Biotechnology Industry? – InvestorsObserver

Ampio Pharmaceuticals Inc (AMPE) is near the top in its industry group according to InvestorsObserver. AMPE gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Ampio Pharmaceuticals Inc gets a 77 rank in the Biotechnology industry. Biotechnology is number 36 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Ampio Pharmaceuticals Inc (AMPE) stock is trading at $1.50 as of 2:05 PM on Tuesday, Jan 19, an increase of $0.15, or 11.11% from the previous closing price of $1.35. The stock has traded between $1.35 and $1.60 so far today. Volume today is low. So far 5,511,356 shares have traded compared to average volume of 10,250,925 shares.

Click Here to get the full Stock Score Report on Ampio Pharmaceuticals Inc (AMPE) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Originally posted here:
Is Ampio Pharmaceuticals Inc (AMPE) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Ampio Pharmaceuticals Inc (AMPE) the Top Pick in the Biotechnology Industry? – InvestorsObserver

When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven? – Simply Wall St

B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. The 166m market-cap company announced a latest loss of 9.7m on 30 September 2020 for its most recent financial year result. The most pressing concern for investors is B.R.A.I.N. Biotechnology Research and Information Network's path to profitability when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

View our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

B.R.A.I.N. Biotechnology Research and Information Network is bordering on breakeven, according to the 6 German Chemicals analysts. They anticipate the company to incur a final loss in 2022, before generating positive profits of 236k in 2023. The company is therefore projected to breakeven around 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 100%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we wont go into details of B.R.A.I.N. Biotechnology Research and Information Network's upcoming projects, however, take into account that typically a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Before we wrap up, theres one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 21% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

This article is not intended to be a comprehensive analysis on B.R.A.I.N. Biotechnology Research and Information Network, so if you are interested in understanding the company at a deeper level, take a look at B.R.A.I.N. Biotechnology Research and Information Network's company page on Simply Wall St. We've also compiled a list of key factors you should look at:

PromotedIf you decide to trade B.R.A.I.N. Biotechnology Research and Information Network, use the lowest-cost* platform that is rated #1 Overall by Barrons, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

See the article here:
When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven? - Simply Wall St

Posted in Biotechnology | Comments Off on When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven? – Simply Wall St